News & Updates

Body mass index (BMI) appears to have no influence over mortality among patients with candidemia, suggests a recent study.

The novel once-daily sustained-release (SR) pregabalin formulation is safe and as good as the twice-daily immediate-release (IR) formulation at reducing peripheral neuropathic pain, according to the results of a phase III trial.

The use of magnesium oxide either alone or in combination with riboflavin may help prevent episodic migraines during pregnancy, according to a study presented at SMFM 2022.

New drug applications approved by US FDA as of 16-28 February 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

For older adults, the efficacy of influenza vaccination is associated with vaccine-circulating strain matching, as reported in a study. If the strains are all matched, the vaccine can reduce the risk of hospitalization for community-acquired pneumonia by up to 28 percent.

Eptinezumab reduces migraine days for both episodic and chronic migraine patients, and the drug’s efficacy and safety profile are independent of age, sex, and body mass index, as shown in a study.